6 completed. 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 6 |
Follow peficitinib: new trials by email Literature Review of peficitinib trials Research Report on peficitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis Placebo, JNJ-54781532 25 mg once daily, JNJ-54781532 75 mg once daily - Colitis, Ulcerative | Phase 2 | Completed | Janssen Research & Development, LLC | 219 | 2013-11-15 | 2019-01-04 |
| A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study peficitinib - Arthritis, Rheumatoid | Phase 2 | Completed | Astellas Pharma Global Development, Inc. | 611 | 2012-09-26 | 2024-10-21 |
| A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate peficitinib, Placebo, methotrexate - Arthritis, Rheumatoid | Phase 2 | Completed | Astellas Pharma Inc | 379 | 2012-07-06 | 2025-05-29 |
| A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis peficitinib, Placebo - Arthritis, Rheumatoid | Phase 2 | Completed | Astellas Pharma Global Development, Inc. | 289 | 2012-06-19 | 2025-05-21 |
| A Study to Evaluate the Efficacy and Safety of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects peficitinib, Placebo - Arthritis, Rheumatoid | Phase 2 | Completed | Astellas Pharma Inc | 281 | 2012-03-01 | 2024-10-21 |
| A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis peficitinib, Placebo - Psoriasis | Phase 2 | Completed | Astellas Pharma Inc | 124 | 2010-03-23 | 2024-10-21 |
Arthritis, Rheumatoid (4) · Colitis, Ulcerative (1) · Lymphoma, Follicular (1) · Motor Activity (1) · Psoriasis (1)
Astellas Pharma Inc (3) · Astellas Pharma Global Development, Inc. (2) · Janssen Research & Development, LLC (1)
United States (5) · Bulgaria (4) · Hungary (4) · Poland (4) · Belgium (3) · Czechia (3) · Mexico (3) · Colombia (2) · Australia (1) · Canada (1) · France (1) · Germany (1) · Israel (1) · Japan (1) · Netherlands (1)
PMID 25704750, PMID 26672064, PMID 27748083, PMID 28118538, PMID 29917064, PMID 30721964, PMID 31410787, PMID 33068028, PMID 33929089